Patrick Y S Lam Selected Research

sulfide quinone reductase

1/2022

Discovery of a first-in-class inhibitor of sulfide:quinone oxidoreductase that protects against adverse cardiac remodelling and heart failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrick Y S Lam Research Topics

Disease

9	Thrombosis (Thrombus) 01/2020 - 12/2003
5	Hemorrhage 01/2020 - 08/2007
1	Heart Failure 01/2022
1	Chronic Hepatitis B 07/2021
1	Carotid Artery Thrombosis 08/2007

Drug/Important Bio-Agent (IBA)

2	Factor XIa (Coagulation Factor XIa)IBA 01/2020 - 01/2020
2	AnticoagulantsIBA 01/2020 - 08/2007
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2020 - 08/2007
2	Clopidogrel (Plavix)FDA Link 03/2014 - 08/2007
2	apixabanIBA 09/2011 - 05/2008
2	Factor Xa (Coagulation Factor Xa)IBA 09/2011 - 12/2003
1	sulfide quinone reductaseIBA 01/2022
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 07/2021
1	Surface Antigens (Surface Antigen)IBA 07/2021
1	EnzymesIBA 01/2020
1	pyridineIBA 01/2020
1	compound 21IBA 01/2016
1	Prasugrel Hydrochloride FDA Link 07/2014
1	Purinergic P2Y1 ReceptorsIBA 06/2014
1	Purinergic P2Y Receptor AntagonistsIBA 06/2014
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 11/2013
1	anthranilamideIBA 05/2008
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2007
1	razaxabanIBA 08/2007
1	Factor Xa InhibitorsIBA 08/2007
1	Peptide Hydrolases (Proteases)FDA Link 08/2006
1	Blood Coagulation Factors (Coagulation Factor)IBA 08/2006

Therapy/Procedure

2	Therapeutics 01/2020 - 08/2007
1	Intravenous Administration 12/2017